资讯

Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing ...

Avidity Biosciences remains a Strong Buy for me, driven by Del-zota's promising data in targeting Duchenne Muscular Dystrophy ...